BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moore K, Jamil K, Verleger K, Luo L, Kebede N, Heisen M, Corman S, Leonardi R, Bakker R, Maï C, Shamseddine N, Huang X, Allegretti AS. Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome. Aliment Pharmacol Ther 2020;52:351-8. [DOI: 10.1111/apt.15836] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Allegretti AS, Parada XV, Endres P, Zhao S, Krinsky S, St Hillien SA, Kalim S, Nigwekar SU, Flood JG, Nixon A, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Regner KR, Belcher JM, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT; HRS-HARMONY study investigators. Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study. Clin Transl Gastroenterol 2021;12:e00359. [PMID: 33979307 DOI: 10.14309/ctg.0000000000000359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Allegretti AS, Jamil K, Moore K. Letter: real-world use of terlipressin in patients with the hepatorenal syndrome-authors' reply. Aliment Pharmacol Ther 2021;54:350-1. [PMID: 34236097 DOI: 10.1111/apt.16486] [Reference Citation Analysis]
3 Moore K, Jamil K, Verleger K, Luo L, Kebede N, Heisen M, Corman S, Leonardi R, Bakker R, Maï C, Shamseddine N, Huang X, Allegretti AS. Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome. Aliment Pharmacol Ther 2020;52:351-8. [DOI: 10.1111/apt.15836] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
4 Weng F. Letter: real‐world use of terlipressin in patients with hepatorenal syndrome. Aliment Pharmacol Ther 2021;54:349-349. [DOI: 10.1111/apt.16449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kulkarni AV, Arab JP, Premkumar M, Benítez C, Tirumalige Ravikumar S, Kumar P, Sharma M, Reddy DN, Simonetto DA, Rao PN. Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives. Liver Int 2020;40:2888-905. [DOI: 10.1111/liv.14703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Qi X, Bai Z, Zhu Q, Cheng G, Chen Y, Dang X, Ding H, Han J, Han L, He Y, Ji F, Jin H, Li B, Li H, Li Y, Li Z, Liu B, Liu F, Liu L, Lin S, Ma D, Meng F, Qi R, Ren T, Shao L, Tang S, Tang Y, Teng Y, Wang C, Wang R, Wu Y, Xu X, Yang L, Yuan J, Yuan S, Yang Y, Zhao Q, Zhang W, Yang Y, Guo X, Xie W. Practice guidance for the use of terlipressin for liver cirrhosis–related complications. Therap Adv Gastroenterol 2022;15:175628482210982. [DOI: 10.1177/17562848221098253] [Reference Citation Analysis]
7 Allegretti AS. Acute Kidney Injury Treatment in Decompensated Cirrhosis: A Focus on Kidney Replacement Therapy. Kidney Med 2021;3:12-4. [PMID: 33604536 DOI: 10.1016/j.xkme.2020.09.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kwong A, Kim WR, Kwo PY, Wang U, Cheng X. Feasibility and Effectiveness of Norepinephrine Outside the Intensive Care Setting for Treatment of Hepatorenal Syndrome. Liver Transpl 2021;27:1095-105. [PMID: 33837624 DOI: 10.1002/lt.26065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Khemichian S, Francoz C, Nadim MK. Advances in management of hepatorenal syndrome. Curr Opin Nephrol Hypertens 2021;30:501-6. [PMID: 34397647 DOI: 10.1097/MNH.0000000000000730] [Reference Citation Analysis]
10 Palaniyappan N, Aithal GP. Editorial: treating hepatorenal syndrome-a window and the views. Aliment Pharmacol Ther 2020;52:895-6. [PMID: 32852817 DOI: 10.1111/apt.15943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Belcher JM, Parada XV, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Sharma P, Regner KR, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT, Allegretti AS; HRS-HARMONY study investigators. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward. Am J Kidney Dis 2021:S0272-6386(21)00890-8. [PMID: 34606933 DOI: 10.1053/j.ajkd.2021.08.016] [Reference Citation Analysis]
12 Pacheco MP, Carneiro-D'Albuquerque LA, Mazo DF. Current aspects of renal dysfunction after liver transplantation. World J Hepatol 2022; 14(1): 45-61 [DOI: 10.4254/wjh.v14.i1.45] [Reference Citation Analysis]
13 Chandna S, Zarate ER, Gallegos-Orozco JF. Management of Decompensated Cirrhosis and Associated Syndromes. Surg Clin North Am 2022;102:117-37. [PMID: 34800381 DOI: 10.1016/j.suc.2021.09.005] [Reference Citation Analysis]